Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 5Endocrine 5Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 32Testicular Neoplasms 13Carcinoma, Ovarian Epithelial 9Testicular Germ Cell Tumor 7Teratoma 7Ovarian Germ Cell Cancer 7Sarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Central Nervous System Neoplasms 4Osteosarcoma 3Neoplasms 3Lung Neoplasms 3Fallopian Tube Neoplasms 3Endodermal Sinus Tumor 3Carcinoma, Non-Small-Cell Lung 3Wilms Tumor 2Uterine Cervical Neoplasms 2Seminoma 2Recurrence 2Optic Nerve Glioma 2Neuroblastoma 2Melanoma 2Medulloblastoma 2Gestational Trophoblastic Disease 2Drug-Related Side Effects and Adverse Reactions 2Desmoplastic Small Round Cell Tumor 2Chondrosarcoma 2Carcinoma, Embryonal 2Brenner Tumor 2Breast Neoplasms 2

Interventions

pembrolizumab 2Magnetic Resonance Spectroscopy 2Irinotecan 2Fluorodeoxyglucose F18 2FAPI-46 2tivozanib 1taxane 1liposomal doxorubicin 1fludarabine 1entrectinib 1atezolizumab 1alectinib 1aldesleukin 1Vinorelbine 1RRx-001 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Paclitaxel 1PM 01183 1Nivolumab 1Molecular Diagnostic Techniques 1Immunotherapy 1Gemcitabine 1Etoposide 1Drug Therapy 1Cyclophosphamide 1Cisplatin 1Carboplatin 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Etoposide × Gynecologic × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡